Boswellia Serrata: The Definitive Guide

What is Boswellia serrata?

Boswellia serrata is a tree whose gum resin is used in oral extracts. “Boswellia,” frankincense, gum resin, bark, essential oil and a standardized extract are not equivalent materials. Human research most often concerns named oral gum-resin extracts for knee osteoarthritis. [1]–[3]

NCCIH says oral boswellia may help osteoarthritis pain, but the studies are mostly small and low quality. A 2024 meta-analysis found no significant overall WOMAC or VAS effect because results were highly heterogeneous, although a placebo subgroup showed a WOMAC signal. [1], [2]

Typical Boswellia Serrata Protocols

There is no RDA, AI or established UL. A proprietary extract's milligrams cannot be converted across products by species name alone.

Titration

No evidence-based self-titration is established. Trial arms were fixed extract-specific schedules.

Timing

Majeed used one tablet after breakfast and dinner. That method does not prove meals improve absorption.

Duration

Recent knee trials lasted 90 days. NCCIH reports apparent safety in several trials up to six months, not proven indefinite safety.

Stopping

Stop and seek review for allergy, severe digestive symptoms, unusual bleeding or worsening joint symptoms.

What is boswellia commonly used for?

Common uses include knee pain, arthritis, mobility, asthma, inflammatory bowel disease and general inflammation. The most relevant clinical evidence concerns knee osteoarthritis. It does not establish disease modification or prove benefit for rheumatoid arthritis, asthma, bowel disease, cancer or generalized “inflammation.” [1], [2]

Which form and label details matter?

Record species, plant part, gum-resin extract name, extraction ratio, milligrams per administration, AKBBA or other boswellic-acid standardization, number of administrations, lot and independent testing. Frankincense essential oil and topical products should not be substituted for oral trial extracts.

What does the human evidence show?

The 2024 meta-analysis included 13 controlled studies; 850 participants contributed WOMAC data and 1,185 contributed VAS data. Overall effects were not significant for WOMAC (p=0.0865) or VAS (p=0.3966) amid high heterogeneity. A subgroup restricted to placebo controls showed a WOMAC signal, but extract, comparator and timing varied. [2]

Majeed 2024 randomized 105 adults to placebo or Boswellin Super 150 or 300 mg twice daily for 90 days; 98 completed. Both active groups improved on pain and function, with no significant difference between active doses. Full text reports that placebo improved on some outcomes, celecoxib rescue was allowed and several authors worked for the manufacturer. [3]

Jayaram 2025 randomized 150 adults with early/non-mild osteoarthritis to BOSMAX or placebo daily for 90 days. The abstract reports better WOMAC, VAS and Lequesne scores but no significant SF-36 change. It does not report the dose or within-day frequency, so this guide does not infer them. [4]

How might it work?

Boswellic acids, including AKBBA, are studied for effects on inflammatory pathways such as 5-lipoxygenase. Marker content varies widely by extract. A laboratory mechanism does not show cartilage regrowth, disease modification or equivalence between products.

What are the risks and interactions?

Boswellia can cause digestive symptoms or allergy. NCCIH says extracts up to 1,000 mg/day have been used with apparent safety for up to six months, and 2,400 mg/day for one month; these observations are not an UL or a recommended dose. [1]

Medicinal-dose safety during pregnancy and breastfeeding is poorly known. Asthma, cancer treatment, anticoagulant or antiplatelet medicines, planned procedures and multiple anti-inflammatory products require professional review. Do not replace prescribed asthma, cancer or arthritis treatment. [1]

Seek urgent care for facial or throat swelling, breathing difficulty, black or bloody stool, severe abdominal pain, sudden hot swollen joint with fever, or inability to bear weight after injury.

Legal status in the United States and Canada

In the United States, oral boswellia products are sold as dietary supplements and are not FDA-approved osteoarthritis treatments. [1]

In Canada, product-specific NPN records exist under monograph-attested conditions. A licence record does not show that all extracts are interchangeable or clinically equivalent. [5]

What should you monitor?

Record extract identity, marker standardization, amount per administration, frequency, rescue pain medicine, pain scale, stiffness, walking function and adverse effects. Keep the same measurement window and avoid attributing natural symptom fluctuation to the supplement.

What happens when you stop?

No withdrawal syndrome or taper is established. Joint symptoms may fluctuate; keep other treatments stable when possible and discuss persistent worsening with a clinician.

How should it be stored?

Follow the label, keep the product dry and away from heat, and preserve lot and expiry details.

How does boswellia compare with other approaches?

Exercise, strength work, weight management when relevant, topical or oral medicines and injections have different evidence and risks. Boswellia is not a substitute for diagnosing inflammatory arthritis, infection or injury.

Turmeric and ginger use different extracts and trial designs. Combining them does not create a proven anti-inflammatory stack.

What do public communities add?

Community reports can flag digestive effects, confusing AKBBA labels and changes in rescue medicine. They cannot distinguish placebo response, natural fluctuation or extract-specific benefit.

Common questions

Does boswellia help knee osteoarthritis?

Possibly for some extract-specific symptom outcomes, but the 2024 overall WOMAC and VAS meta-analyses were not significant and heterogeneity was high. [2]

Is 600 mg once daily the 2024 trial schedule?

No. The high arm used 300 mg after breakfast and 300 mg after dinner. [3]

Are all Boswellia extracts equivalent?

No. Species, gum-resin processing and boswellic-acid standardization differ.

Does it rebuild cartilage?

No clinical evidence here establishes cartilage regrowth or disease modification.

Does it treat rheumatoid arthritis or inflammatory bowel disease?

Knee-osteoarthritis evidence should not be transferred to those conditions.

Is it safe in pregnancy?

Food amounts may be acceptable, but medicinal-dose safety is poorly known. [1]

Can it replace an NSAID?

No automatic substitution is established. Medication changes require clinical review.

Why record rescue medicine?

Because it can change pain and function, and the 2024 trial allowed celecoxib rescue. [3]

Glossary

Terms used in this guide.

AKBBA

A boswellic-acid marker used to standardize some extracts.

WOMAC

A questionnaire measuring osteoarthritis pain, stiffness and physical function.

Visual analog scale

A scale used to rate symptom intensity such as pain.

Heterogeneity

Meaningful variation among studies in interventions, methods or results.

Rescue medicine

Allowed additional treatment used when symptoms require relief.

Titration

Planned dose adjustment; no self-titration schedule is established here.

How this guide was researched

This draft prioritized NCCIH's April 2025 summary, the independent 2024 meta-analysis, full text of the 2024 Boswellin trial, the 2025 BOSMAX abstract and a Canadian licence record. It preserves extract, administration and conflict-of-interest details. Evidence was refreshed October 9, 2026.

How this guide was made

The ledger records exact schedules, standardization, co-treatment, comparator and source access.

Sources

Related guides